CD19-STAR-T Cells is under clinical development by China Immunotech and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData, Phase I drugs for B-Cell Non-Hodgkin Lymphoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CD19-STAR-T Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CD19-STAR-T Cells overview
Gene therapy is under development for the treatment of refractory and relapsed of B-cell malignancies including acute lymphocytic leukemia and B-cell non-Hodgkin lymphoma. It acts by targeting cells expressing CD-19. The therapeutic candidate consists of autologous T cells genetically engineered with lentiviral vector encoding synthetic T cell antigen receptor (STAR). The drug candidate is administered by intravenous route as infusion.
China Immunotech overview
China Immunotech (Beijing) Biotechnology Co., Ltd., a biotechnology company that engaged in biopharmaceutics research and development. The company is headquartered in China.
For a complete picture of CD19-STAR-T Cells’s drug-specific PTSR and LoA scores, buy the report here.